Organogenesis Inc. signed a licensing deal with Integra LifeSciences Corp. for its FortaFlex tendon repair technology.
The Canton-based tissue regeneration firm will provide the product to Integra for the Plainsboro, N.J.-based company’s Inforce Reinforcement Matrix, aimed at the estimated $1.2 billion tendon repair market.
Integra plans to unveil the collaboration today at the Annual Summer Meeting of the American Orthopaedic Foot & Ankle Society in Vancouver. Terms of the deal were not disclosed.
The FortaFlex technology is a family of collagen-based biomaterials for use in hernial repair, uro-gynecology and tendon repair. The company’s FortaGen product won 510(K) clearance from the Food and Drug Administration for use in repairing torn rotator cuffs, patellar and Achilles tendons. Organogenesis is actively shopping for licensing deals for the technology, according to its website.
Integra, a leading regenerative medicine firm, pulled in more than $650 million in sales last year. The company employs about 2,800 people across the globe, according to its most recent earnings report.
In other news, Organogenesis was hailed as a success story in a recent article of Business Week magazine, which chronicled the company’s rocky 25-year journey to stability in a story titled“The Failed Promise of Innovation in the U.S.”